Trastuzumab duocarmazine clinical trials
Also written SYD985.
How each study uses trastuzumab duocarmazine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the trastuzumab duocarmazine studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2020 (2)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2014 | 1 |
| 2017 | 1 |
| 2020 | 2 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 2
Often tested with
Tested in the same studies.
Trastuzumab (1) · Ganitumab (1) · Ado-Trastuzumab Emtansine (1) · Pertuzumab (1) · STA 9090 (1) · Veliparib (1) · Neratinib (1) · Pexidartinib (1)
Studies
Open first, then newest update. How each study uses trastuzumab duocarmazine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingPhase 2QuantumLeap Healthcare CollaborativeNCT01042379Written as SYD985 ([vic-]trastuzumab duocarmazine)
- SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial CarcinomaCompletedPhase 2Byondis B.V.NCT04205630Written as SYD985
- Phase I Study of SYD985 With Niraparib in Patients With Solid TumorsCompletedPhase 1Byondis B.V.NCT04235101Written as SYD985 + Niraparib
- ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic CancerWithdrawnPhase 1QuantumLeap Healthcare CollaborativeNCT04602117Written as Vic-trastuzumab duocarmazine (SYD985) + paclitaxel
- SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast CancerCompletedPhase 3Byondis B.V.NCT03262935Written as (vic-)trastuzumab duocarmazine
- First-in-human Study With the Antibody-drug Conjugate SYD985 to Evaluate Safety and Efficacy in Cancer PatientsCompletedPhase 1Byondis B.V.NCT02277717Written as SYD985 (trastuzumab vc-seco-DUBA)
Codes
What other systems call trastuzumab duocarmazine · ClinicalTrials.gg INT001247
- MeSH (NLM) C000656468trastuzumab duocarmazineOne source NLM
- UNII (FDA) XCR2BZ80N7TRASTUZUMAB DUOCARMAZINEConfirmed FDA, NLM
- NCI Thesaurus C118674Trastuzumab DuocarmazineOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000656468 | trastuzumab duocarmazine | One source NLM |
| UNII (FDA) | XCR2BZ80N7 | TRASTUZUMAB DUOCARMAZINE | Confirmed FDA, NLM |
| NCI Thesaurus | C118674 | Trastuzumab Duocarmazine | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.